Clinical efficacy of recombinant factor VIII

Steven Arkin, Esther Rose, Alice Forster, Louis M. Aledort

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

This investigation has been an ongoing, multistage evaluation of the pharmacokinetics, safety and efficacy of a factor VIII concentrate prepared through recombinant DNA technology. In vivo activity of the rFVIII has been comparable to that of pdFVIII including half life and in vivo recovery. Recombinant factor VIII is safe and effective for prophylaxis and treatment of hemophilic bleeding episodes. Efficacy of rFVIII appears comparable with that of pdFVIII concentrates. Infusions were well tolerated with infrequent adverse reactions. As with any new product, the verdict regarding induction of inhibitors to factor VIII awaits evaluation of sufficient numbers of patients and passage of adequate observation time.

Original languageEnglish
Pages (from-to)47-51
Number of pages5
JournalSeminars in Hematology
Volume28
Issue number2 SUPPL. 1
StatePublished - Apr 1991

Fingerprint

Dive into the research topics of 'Clinical efficacy of recombinant factor VIII'. Together they form a unique fingerprint.

Cite this